Titre
Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Rudin, C.
Auteure/Auteur
Wolbers, M.
Auteure/Auteur
Nadal, D.
Auteure/Auteur
Rickenbach, M.
Auteure/Auteur
Bucher, H.C.
Auteure/Auteur
Contributrices/contributeurs
Aebi, C.
Bär, W.
Berger, Ch.
Besson, F.
Bühlmann, U.
Cheseaux, JJ.
Desgrandchamps, D.
Diana, A.
Duppenthaler, A.
Gervaix, A.
Gnehm, HP.
Heininger, U.
Hunziker, UA.
Kahlert, C.
Kind, C.
Kuchler, H.
Loher, A.
Masserey-Spicher, V.
Myers, C.
Nadal, D.
Posfay-Barbe, C.
Rudin, C.
Schaad, UB.
Siegrist, CA.
Stähelin, J.
Vaudaux, B.
Wyler-Lazarevic, CA.
Zingg, W.
Aebi, C.
Battegay, M.
Bernasconi, E.
Böni, J.
Brazzola, P.
Bucher, HC.
Bürgisser, P.
Calmy, A.
Cattacin, S.
Cavassini, M.
Cheseaux, JJ.
Drack, G.
Dubs, R.
Egger, M.
Elzi, L.
Fischer, M.
Flepp, M.
Fontana, A.
Francioli, P.
Furrer, HJ.
Fux, C.
Gayet-Ageron, A.
Gerber, S.
Gorgievski, M.
Günthard, H.
Gyr, T.
Hirsch, H.
Hirschel, B.
Hösli, I.
Hüsler, M.
Kaiser, L.
Kahlert, Ch.
Karrer, U.
Kind, C.
Klimkait, T.
Ledergerber, B.
Martinetti, G.
Martinez, B.
Müller, N.
Nadal, D.
Paccaud, F.
Pantaleo, G.
Raio, L.
Rauch, A.
Regenass, S.
Rickenbach, M.
Rudin, C.
Schmid, P.
Schultze, D.
Schüpbach, J.
Speck, R.
Taffé, P.
Telenti, A.
Trkola, A.
Vernazza, P.
Weber, R.
Wyler, CA.
Yerly, S.
Groupes de travail
Pediatric Infectious Disease Group of Switzerland (PIGS)
Swiss Mother
Child HIV Cohort Study (MoCHiV)
Liens vers les personnes
Liens vers les unités
ISSN
1468-2044
Statut éditorial
Publié
Date de publication
2010
Volume
95
Numéro
6
Première page
478
Dernière page/numéro d’article
481
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Résumé
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children.
METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included.
RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children.
CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.
METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included.
RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children.
CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.
Sujets
PID Serval
serval:BIB_5E884C0CA0D9
PMID
Date de création
2010-12-29T15:46:44.702Z
Date de création dans IRIS
2025-05-20T15:41:21Z